<DOC>
	<DOC>NCT00095147</DOC>
	<brief_summary>The purpose of this clinical research study is to learn if Abatacept or Infliximab in combination with Methotrexate demonstrate a greater reduction in disease activity over placebo.</brief_summary>
	<brief_title>Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Diagnosis of Rheumatoid Arthritis At least 3 months prior treatment with Methotrexate (MTX) At least 10 swollen joints and 12 tender joints and CReactive Protein of at least 1 mg/dl Washout required for other disease modifying antirheumatic drugs (DMARDS) participants who have failed more than 3 DMARDs participants previously treated with an approved biologic drug History of cancer in the last 5 years Severe or recurrent bacterial infection Any previous or current medical conditions that are contraindications to the use of TNF blocking agents Women of Child Bearing Potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>